We, LTT Bio-Pharma, have been applying cutting-edge science and technology to medicine for more than 30 years, have been conducting research and development to protect the health and lives of people all over the world.
Research and Development
We will introduce our original drug discovery technologies, pipeline under development, and launched drugs.
DR
Drug Repositioning
We were the first in Japan to point out the importance of DR and have been promoting drug discovery as a leading
DR company. We are also engaged in collaborative research using our own original library of approved drugs.
DDS
Drug Delivery System
Like DR, DDS contributes to early commercialization and reduced development risk. We have launched DDS new drug and are still developing new drugs using the world’s first DDS technology.
Collaborative R&D
and Consultation
Through joint development, we connect academia and pharmaceutical companies to efficiently develop pharmaceuticals.
Founding Family
創業者と創業家 / 水島徹 & 水島広子
Corporate Information
Careers
IR Information
- All
- Business Development
- Drug Discovery
- General Meeting of Shareholders
- Financial Information
- Other
-
2026.03.12
Notice of Initiation of Phase III Clinical Trial (Physician-Initiated Trial) for LT-5001 in Trigeminal Neuralgia
-
2026.03.10
Request for notification of changes to shareholder register entries, such as address changes
-
2026.03.09
Announcement of Completion of Investigational Drug Administration in the Phase IIa Clinical Trial of PC-SOD
-
2026.01.23
Notice of Presentation at ASCO-GI 2026 Regarding Our Phase III Clinical Trial
-
2026.03.12
Notice of Initiation of Phase III Clinical Trial (Physician-Initiated Trial) for LT-5001 in Trigeminal Neuralgia
-
2026.03.09
Announcement of Completion of Investigational Drug Administration in the Phase IIa Clinical Trial of PC-SOD
-
2026.01.23
Notice of Presentation at ASCO-GI 2026 Regarding Our Phase III Clinical Trial
-
2025.12.01
Announcement of Publication of Phase IIa Clinical Trial Results for PC-SOD
-
2025.06.25
Notice of Resolutions of the 23rd Ordinary General Meeting of Shareholders
-
2025.06.05
Partial correction of the contents of the” Announcement of the 23rd Ordinary General Meeting of Shareholders”
-
2025.06.05
Announcement of the 23rd Ordinary General Meeting of Shareholders
-
2025.03.18
Notice of Resolutions of the 22nd Ordinary General Meeting of Shareholders
-
2026.03.10
Request for notification of changes to shareholder register entries, such as address changes
-
2025.11.01
Notice of Consulting Services Contract Conclusion with New Securities Firm
-
2025.09.24
Our CEO (Director of the Japan Biotechnology Association) made a statement at the Central Social Insurance Medical Council
-
2025.09.10
Request for notification of changes to shareholder register entries, such as address changes